Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Authorizes $300M Share Repurchase Program

NEW YORK (GenomeWeb) – Bruker said today that its board of directors has authorized a new share repurchase program under which it may purchase up to $300 million of its common stock over a two-year period beginning May 14, 2019.

The company will fund the repurchases with cash on hand and funds from its existing credit facility. The authorization does not obligate Bruker to purchase any specific number of shares and may be suspended, modified, or terminated at any time, the company said.

"Bruker's ongoing margin expansion, financial health, and positive outlook for the future support the continuation of our share repurchases with a new $300 million, two-year authorization," Gerald Herman, the company's CFO, said in a statement.

The company also announced that its board has authorized payment of a quarterly cash dividend of $0.04 per share of its common stock that will first be paid on June 21, 2019 to stockholders of record as of June 3, 2019.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.